相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。How to Train Your T Cells: Overcoming Immune Dysfunction in Multiple Myeloma
Adam D. Cohen et al.
CLINICAL CANCER RESEARCH (2020)
Cancer statistics, 2020
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2020)
Preclinical Activity of JNJ-7957, a Novel BCMAxCD3 Bispecific Antibody for the Treatment of Multiple Myeloma, Is Potentiated by Daratumumab
Kristine A. Frerichs et al.
CLINICAL CANCER RESEARCH (2020)
Anti-B-Cell Maturation Antigen BiTE Molecule AMG 420 Induces Responses in Multiple Myeloma
Max S. Topp et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
A class of costimulatory CD28-bispecific antibodies that enhance the antitumor activity of CD3-bispecific antibodies
Dimitris Skokos et al.
SCIENCE TRANSLATIONAL MEDICINE (2020)
Bispecific Antibodies for Multiple Myeloma: A Review of Targets, Drugs, Clinical Trials, and Future Directions
Chiara Caraccio et al.
FRONTIERS IN IMMUNOLOGY (2020)
Efficient tumor killing and minimal cytokine release with novel T-cell agonist bispecific antibodies
Nathan D. Trinklein et al.
MABS (2019)
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
Noopur Raje et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
leExploratory trial of a biepitopic CAR T-targeting B cell maturation antigen in relapsed/refractory multiple myeloma
Jie Xu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)
Bispecific antibodies: a mechanistic review of the pipeline
Aran F. Labrijn et al.
NATURE REVIEWS DRUG DISCOVERY (2019)
A Mucin 16 bispecific T cell-engaging antibody for the treatment of ovarian cancer
Alison Crawford et al.
SCIENCE TRANSLATIONAL MEDICINE (2019)
Clinical lessons learned from the first leg of the CAR T cell journey
Robbie G. Majzner et al.
NATURE MEDICINE (2019)
CD3 bispecific antibody-induced cytokine release is dispensable for cytotoxic T cell activity
Ji Li et al.
SCIENCE TRANSLATIONAL MEDICINE (2019)
Combination Immunotherapy with CAR T Cells and Checkpoint Blockade for the Treatment of Solid Tumors
Rachel Grosser et al.
CANCER CELL (2019)
CD19 chimeric antigen receptor-T cells in B-cell leukemia and lymphoma: current status and perspectives
Mohamad Mohty et al.
LEUKEMIA (2019)
Redirected T Cell Cytotoxicity in Cancer Therapy
Raphael A. Clynes et al.
ANNUAL REVIEW OF MEDICINE, VOL 70 (2019)
CD3-Bispecific Antibody Therapy Turns Solid Tumors into Inflammatory Sites but Does Not Install Protective Memory
Hreinn Benonisson et al.
MOLECULAR CANCER THERAPEUTICS (2019)
Integrated Pharmacokinetic/Pharmacodynamic Model of a Bispecific CD3xCD123 DART Molecule in Nonhuman Primates: Evaluation of Activity and Impact of Immunogenicity
Olivia Campagne et al.
CLINICAL CANCER RESEARCH (2018)
Effective Targeting of Multiple B-Cell Maturation Antigen-Expressing Hematological Malignances by Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor T Cells
Kevin M. Friedman et al.
HUMAN GENE THERAPY (2018)
T Cells Genetically Modified to Express an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma
Jennifer N. Brudno et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1/PD-L1 pathway
Rosemarie Tremblay-LeMay et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2018)
Chimeric Antigen Receptor Therapy
Carl H. June et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
S. L. Maude et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Phosphoproteomic analysis of chimeric antigen receptor signaling reveals kinetic and quantitative differences that affect cell function
Alexander I. Salter et al.
SCIENCE SIGNALING (2018)
PD1 is expressed on exhausted T cells as well as virus specific memory CD8+ T cells in the bone marrow of myeloma patients
Anne-Marit Sponaas et al.
Oncotarget (2018)
Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy
Shih-Feng Cho et al.
FRONTIERS IN IMMUNOLOGY (2018)
Mouse Models for Cancer Immunotherapy Research
Brian Olson et al.
CANCER DISCOVERY (2018)
Allogeneic CAR-T Cells: More than Ease of Access?
Charlotte Graham et al.
CELLS (2018)
Targeting the PD-1/PD-L1 axis in multiple myeloma: a dream or a reality?
Jacalyn Rosenblatt et al.
BLOOD (2017)
Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study
S. K. Kumar et al.
LEUKEMIA (2017)
A novel BCMA/CD3 bispecific T-cell engager for the treatment of multiple myeloma induces selective lysis in vitro and in vivo (vol 31, pg 1743, 2017)
S. Hipp et al.
LEUKEMIA (2017)
Target Expression, Generation, Preclinical Activity, and Pharmacokinetics of the BCMA-T Cell Bispecific Antibody EM801 for Multiple Myeloma Treatment
Anja Seckinger et al.
CANCER CELL (2017)
T Cell Redirecting Therapies for Cancer Treatment
Barbra Sasu et al.
CURRENT CANCER DRUG TARGETS (2016)
Novel immunotherapies in lymphoid malignancies
Connie Lee Batlevi et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2016)
Development of purification processes for fully human bispecific antibodies based upon modification of protein A binding avidity
Andrew D. Tustian et al.
MABS (2016)
γ-secretase directly sheds the survival receptor BCMA from plasma cells
Sarah A. Laurent et al.
NATURE COMMUNICATIONS (2015)
A novel, native-format bispecific antibody triggering T-cell killing of B-cells is robustly active in mouse tumor models and cynomolgus monkeys
Eric J. Smith et al.
SCIENTIFIC REPORTS (2015)
Mice with megabase humanization of their immunoglobulin genes generate antibodies as efficiently as normal mice
Andrew J. Murphy et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
Therapeutic advancements in multiple myeloma
Alessandro Gozzetti et al.
FRONTIERS IN ONCOLOGY (2014)
B-cell Maturation Antigen Is a Promising Target for Adoptive T-cell Therapy of Multiple Myeloma
Robert O. Carpenter et al.
CLINICAL CANCER RESEARCH (2013)
Blinatumomab: A historical perspective
Dirk Nagorsen et al.
PHARMACOLOGY & THERAPEUTICS (2012)
Targeted Therapy With the T-Cell-Engaging Antibody Blinatumomab of Chemotherapy-Refractory Minimal Residual Disease in B-Lineage Acute Lymphoblastic Leukemia Patients Results in High Response Rate and Prolonged Leukemia-Free Survival
Max S. Topp et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Mode of cytotoxic action of T cell-engaging BiTE antibody MT110
Cornelia Haas et al.
IMMUNOBIOLOGY (2009)
Human bone marrow:: A reservoir for enhanced effector memory CD8+ T cells with potent recall function
Xiaoyu Zhang et al.
JOURNAL OF IMMUNOLOGY (2006)
High-throughput engineering of the mouse genome coupled with high-resolution expression analysis
DM Valenzuela et al.
NATURE BIOTECHNOLOGY (2003)
Requirements for presenilin-dependent cleavage of notch and other transmembrane proteins
G Struhl et al.
MOLECULAR CELL (2000)
分享论文
